Pfizer has its sights set on AstraZeneca for $100 billion

Pfizer's nearly $100 billion acquisition bid for AstraZeneca makes sense for both drug makers, but likely won't get done unless the offer is “sweetened”

Mergers and acquisitions have been a hot topic throughout the drug industry lately, as companies face slowing sales and rising costs. In fact, deals worth $128 billion have been announced in the sector so far this year, according to Dealogic. This is the highest total since 2009.

As of late, Pfizer Inc.’s $100 billion bid for AstraZeneca is the largest and most recent in a series of proposed big pharma mergers. Pfizer has a new approach to AstraZeneca PLC regarding a takeover valued at almost $100 billion, but the U.K.-listed pharmaceutical firm declined to discuss further.

Contributing Author

author image

Amanda Ciccatelli

Amanda G. Ciccatelli is a Contributing Writer for InsideCounsel, where she covers the patent litigation space. Amanda earned a B.A. in Communications and Journalism from...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.